VSIR and prostate carcinoma: VISTA is also known to be upregulated on tumor cells in cancers such as mesothelioma, ovarian cancer, gastric cancer, and NSCLC43–46, and upregulated in prostate cancer upon treatment with anti-CTLA4 antibody8.